跳至主要内容
临床试验/NCT01657747
NCT01657747已完成不适用

Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer

Universitaire Ziekenhuizen KU Leuven2 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2011年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
350
试验地点
2
主要终点
Validation of interpretation criteria of WB-DWI for staging and thresholding for treatment assessment in pilot study

研究概览

简要总结

The aim of this study is to assess whole body diffusion weighted imaging (WB-DWI) as a non-invasive method for

  • accurate staging of patient suspected having ovarian cancer
  • early treatment assessment
  • detecting tumor recurrence

详细描述

  1. Staging --- (PET-)CT is used nowadays to provide imaging information about the disease burden of ovarian cancer patients and a diagnostic staging laparoscopy under general anesthesia is often necessary to allow correct and accurate staging. The applicant propose an "all-in-one" imaging modality providing high quality thoracic-abdominal images without using ionizing radiation and/or radioactive material. This allows accurate assessment of operability in a minimally invasive manner.
  2. Early treatment assessment --- Although response to the first administration of chemotherapy is quite reasonable, most patients show tumor recurrence and achieve increasingly poorer response rates to second- or third-line regimes. Therefore it is of major concern that a individualized prediction of chemosensitivity can be performed avoiding unnecessary toxicity from inefficient chemotherapeutic agents. A promising perspective is that the predictive data to be generated might prove to be sufficiently powerful to predict chemosensitivity early in the course of the treatment, facilitating a timely change of treatment in nonresponders. This could avoid unnecessary toxicity for patients, improving quality of life and moreover implicate considerable savings for the healthcare sector.
  3. Identifying tumor recurrence --- Identifying tumor recurrence at an early stage could translate into reduction of unnecessary biopsies, cost savings and reduced morbidity associated with the biopsy procedure. But the most important issue is that early diagnosis can be life saving with respect to tumor recurrence.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
Single (Investigator)

入排标准

性别
Female
接受健康志愿者

入选标准

  • STAGING: patients with suspected ovarian carcinoma
  • EARLY TREATMENT ASSESSMENT: patients with FIGO stage IIIc or IV ovarian carcinoma who will undergo neoadjuvant chemotherapy
  • IDENTIFYING TUMOR RECURRENCE: patients with a medical history of ovarian carcinoma with suspicion of recurrent ovarian cancer after a disease-free-interval of at least 6 months

排除标准

  • patients with known contra-indications for MRI (cardiac pacemakers, cochlear implants, claustrophobic patients)will be excluded from this study.
  • patients with contra-indications to gadolinium-based contrast agents (including patients with a known restricted renal function; GFR < 30 mL/min)and/or Buscopan

结局指标

主要结局

Validation of interpretation criteria of WB-DWI for staging and thresholding for treatment assessment in pilot study

时间窗: Nov 2011 - Sep 2012 (up to 1 year)

Validation of interpretation criteria of WB-DWI for staging and thresholding for treatment assessment in pilot study

WB-DWI for tumor characterization and staging at primary diagnosis

时间窗: Nov 2011 - Nov 2015 (expected) (up to 4 years)

The aim of this part of the study is to prospectively evaluate WB-DWI for tumor characterization and staging at primary diagnosis in comparison to CT and combined CT/diagnostic laparoscopy with the aim to assess patient operability.

WB-DWI for response assessment during and early after neoadjuvant chemotherapy

时间窗: Nov 2011 - Nov 2015 (expected) (up to 4 years)

The aim of this part of the study is to prospectively evaluate WB-DWI for (early) response assessment during and early after neoadjuvant chemotherapy in comparison to CT with the aim to predict chemotherapy induced tumor load regression and subsequent operability

次要结局

  • The prognostic value of DWI-determined imaging markers(Nov 2013 - Nov 2015 (expected) (up to 2 years))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验